Barry Kiely

TL;DR: B infantis 35624 alleviates symptoms in IBS; this symptomatic response was associated with normalization of the ratio of an anti-inflammatory to a proinflammatory cytokine, suggesting an immune-modulating role for this organism, in this disorder.

TL;DR: Criteria for in vitro selection of probiotic bacteria that may reflect certain in vivo effects on the host such as modulation of gastrointestinal tract microflora is developed.

TL;DR: Findings point to a more influential role for bifidobacteria in neural function, and suggest that probiotics may have broader therapeutic applications than previously considered.

TL;DR: B. infantis 35624 at a dose of 1 × 108 cfu was significantly superior to placebo and all other bifidobacterium doses for the primary efficacy variable of abdominal pain as well as the composite score and scores for bloating, bowel dysfunction, incomplete evacuation, straining, and the passage of gas at the end of the 4-wk study.

TL;DR: Both Lactobacillus salivarius and Bifidobacterium infantis 35624 significantly attenuate colitis in this murine model, associated with a reduced ability to produce Th1-type cytokines systemically and mucosally while levels of TGF-β are maintained.